Licensing Long-Term Care Facilities Therapies 
The Pharma Data
DECEMBER 19, 2020
Today’s ACIP recommendation follows the December 1, 2020 ACIP recommendation for a Phase 1a rollout in which the first priority for COVID-19 vaccines is given to healthcare personnel treating patients and residents in long-term care facilities. Department of Health and Human Services (HHS) for review and adoption.
The Pharma Data
APRIL 14, 2021
government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 25, 2021
Given the importance of finding therapies for COVID-19 and to help interpret trial results during the pandemic, additional analyses were performed and are being communicated (Table 1). health care workers, long-term care facility workers, and workers in occupational or industrial settings in which close contact is common.
The Pharma Data
NOVEMBER 9, 2020
“We’re proud of the speed with which we have been able to bring patients this therapy specifically designed to treat COVID-19. Bamlanivimab remains an investigational drug and has not been approved under a Biologics License Application (BLA). who require oxygen therapy due to COVID-19, OR.
The Pharma Data
MAY 4, 2021
INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. It is approved in the U.S.
The Pharma Data
APRIL 16, 2021
who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. Bamlanivimab and etesevimab together are not authorized for use in patients: who are hospitalized due to COVID-19, OR.
The Pharma Data
MARCH 5, 2021
The opinion can now be considered by the EU member states when making decisions on the use of the therapies at a national level before a formal marketing authorization is issued. Lilly Antibody Therapies Around the World. who require oxygen therapy due to COVID-19, OR. Ricks, Lilly’s chairman and CEO.
Expert insights. Personalized for you.
Let's personalize your content